Case Studies

Milan Patel, PharmD; Elizabeth S. Mearns, PharmD; and Craig I. Coleman, PharmD
Published Online: Tuesday, June 17, 2014
Follow Pharmacy_Times:
Case 1
AR, a 55-year-old African American man, comes to your pharmacy to fill a new prescription. He tells you that he recently received a diagnosis of primary hypertension from his doctor and was given a prescription for lisinopril 10 mg once daily. He has no other comorbidities, such as diabetes or chronic kidney disease.
As the pharmacist, should you dispense this medication?

Case 2
BF is a 49-year-old man who comes to the pharmacy with a new prescription for flecainide 50 mg every 12 hours. He had recently been released from the hospital for an episode of paroxysmal atrial fibrillation (AF) and was discharged with instructions to begin taking flecainide for rhythm control. Upon review of the patient’s profile, you notice he is also on carvedilol, lisinopril, aspirin, and atorvastatin. After talking to the patient, you learn he had a myocardial infarction (MI) a few years ago.
As the pharmacist, do you fill the prescription for this patient?

Dr. Patel is a pharmacist, Dr. Mearns is health economics and outcomes research fellow at Hartford Hospital Evidence-Based Practice Center, and Dr. Coleman is professor of pharmacy practice, as well as codirector and methods-chief at Hartford Hospital Evidence-Based Practice Center, at the University of Connecticut School of Pharmacy.


Related Articles
Adolescents exposed to gestational diabetes in utero have a higher risk of developing impaired glucose tolerance.
Hospitalization rates for heart disease and stroke have dropped significantly over the past decade.
The FDA has approved the first zinc transporter 8 autoantibody test that may help patients with type 1 diabetes mellitus receive more timely diagnosis and treatment for the disease.
Amgen’s investigational treatment for secondary hyperparathyroidism in patients with chronic kidney disease who are receiving hemodialysis achieved its primary and secondary endpoints in a second Phase 3 study.
Latest Issues
$auto_registration$